Targeting the CCL5/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer
Our findings identify the CCL5/CCR5 axis as a key mediator of tumor-stromal crosstalk driving cisplatin resistance in NEPC. Mechanistically, CAF-derived CCL5 activates AKT signaling in tumor cells by promoting the formation of the CCR5/β-arrestin1/p85 complex. Targeting this pathway with maraviroc in combination with cisplatin offers a promising therapeutic strategy for overcoming drug resistance in NEPC.
Authors
- Jiahua Pan (ORCID: https://orcid.org/0000-0002-8559-7170)
- Yiyi Ji (ORCID: https://orcid.org/0000-0001-5598-0059)
- Jiajin Wu (ORCID: https://orcid.org/0000-0003-2780-8272)
- Zehua Ma
- Xinyu Chai (ORCID: https://orcid.org/0000-0003-2702-665X)
- Kai Shen (ORCID: https://orcid.org/0000-0003-4699-1869)
- Xinyu Liu (ORCID: https://orcid.org/0000-0001-7495-442X)
- Weiwei Zhang (ORCID: https://orcid.org/0000-0001-5525-2852)
- Bo Liu (ORCID: https://orcid.org/0000-0002-0536-6197)
- Liang Dong
- Cong Hu (ORCID: https://orcid.org/0000-0002-5309-5985)
- Wei Xue (ORCID: https://orcid.org/0000-0003-3658-9446)
- Baijun Dong (ORCID: https://orcid.org/0000-0001-7622-3946)
- Haotian Wu (ORCID: https://orcid.org/0009-0004-6068-2960)
- Zhou Jiang (ORCID: https://orcid.org/0000-0002-4776-429X)
- Yinjie Zhu (ORCID: https://orcid.org/0009-0002-2937-210X)
- Ang Li (ORCID: https://orcid.org/0000-0001-7578-1911)
- Ruopeng Su (ORCID: https://orcid.org/0000-0002-8160-3959)
- Qi Wang (ORCID: https://orcid.org/0009-0003-2901-1301)
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s13046-025-03552-y
- Citations
- 3
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 3.14